verogalid er 240 mg
teva pharmaceuticals slovakia s.r.o., slovensko - verapamil - 83 - vasodilatantia
coloxet 500 mg
egis pharmaceuticals plc, maďarsko - kapecitabín - 44 - cytostatica
coloxet 300 mg
egis pharmaceuticals plc, maďarsko - kapecitabín - 44 - cytostatica
coloxet 150 mg
egis pharmaceuticals plc, maďarsko - kapecitabín - 44 - cytostatica
ivabradine glenmark 7,5 mg
glenmark pharmaceuticals s.r.o., Česká republika - ivabradín - 41 - cardiaca
ivabradine glenmark 5 mg
glenmark pharmaceuticals s.r.o., Česká republika - ivabradín - 41 - cardiaca
ivabradine glenmark 2,5 mg
glenmark pharmaceuticals s.r.o., Česká republika - ivabradín - 41 - cardiaca
rasagiline egis 1 mg tablety
egis pharmaceuticals plc, maďarsko - razagilín - 27 - antiparkinsonica
fulvestrant teva 250 mg
teva pharmaceuticals slovakia s.r.o., slovensko - fulvestrant - 34 - antihormona
orserdu
stemline therapeutics b.v. - elacestrant - neoplazmy prsníkov - endokrinná terapia - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.